New targeted drug BAT8008 enters human testing for Hard-to-Treat cancers

NCT ID NCT05620017

Recruiting now Disease control Sponsor: Bio-Thera Solutions Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug called BAT8008 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target a protein called Trop2 found on many cancer cells. The main goals are to check safety, find the best dose, and see initial signs of tumor shrinkage. About 182 participants will receive the drug by infusion every two weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BAT8008 (a Trop2-targeting antibody-drug conjugate)
What this could lead to: If successful, this could lead to a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is an early Phase 1 trial focused on safety and dosing, so it is too soon to know if the drug will be effective. Side effects may occur, and the drug may not work for all tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Affiliated Cancer Hospital of Chongqing University
RECRUITING

Chongqing, Chongqing Municipality, China
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.